Výsledky vyhledávání

A211 INCIDENCE OF PRIMARY SCLEROSING CHOLANGITIS: A META-ANALYSIS OF POPULATION-BASED STUDIES

Autor: J Cooper, A Markovinovic, S Coward, A M Shaheen, M Swain, R Panaccione, C Ma, K L Novak, G G Kaplan

Publikováno v: Journal of the Canadian Association of Gastroenterology. 5:98-99

Background Primary sclerosing cholangitis (PSC) is a chronic liver disease associated with significant morbidity, mortality and healthcare utilization. Understanding the incidence of PSC is important in defining the burden of disease and planning for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a1819260477e5734c63d06d9dcbbb542
https://doi.org/10.1093/jcag/gwab049.210

Zobrazit plný text záznamu

A97 DEVELOPMENT OF PREDICTION MODELS FOR THE TRIAGING OF REFERRALS OF INDIVIDUALS WITH SUSPECTED INFLAMMATORY BOWEL DISEASE TO IMPROVE PROMPT ACCESS TO CARE

Autor: J St-Pierre, A Frolkis, C Seow, J Oshiomogho, G Bindra, J Heatherington, G G Kaplan, R Panaccione, K L Novak, Y Nasser, H Jijon

Publikováno v: Journal of the Canadian Association of Gastroenterology. 5:112-113

Background The negative impact of a delayed inflammatory bowel disease (IBD) diagnosis has been well established. We created a clinical pathway referred to as the “High-Risk IBD clinic” within a centralized referral program in a tertiary referral

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f8c57ed012fa71173dd53d06728a410f
https://doi.org/10.1093/jcag/gwab049.096

Zobrazit plný text záznamu

A173 INNOVATIVE CARE FOR INFLAMMATORY BOWEL DISEASE PATIENTS DURING THE COVID-19 PANDEMIC: USE OF BEDSIDE INTESTINAL ULTRASOUND TO OPTIMIZE MANAGEMENT

Autor: K L Novak, C Ma, H Kheirkhahrahimabadi, j heatherington, R Ingram, M Martin, R Panaccione, G G Kaplan, S Devlin, C Seow, M Chan, C Lu

Publikováno v: Journal of the Canadian Association of Gastroenterology. 4:184-185

Background The COVID-19 pandemic has led to significant alterations in the ability to deliver outpatient care to patients with inflammatory bowel disease (IBD) including endoscopic evaluation. This has highlighted the need for alternative, accurate,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::adfa409388c0abc70391b69916e993d3
https://doi.org/10.1093/jcag/gwab002.171

Zobrazit plný text záznamu

A108 USTEKINUMAB IS EFFECTIVE FOR INDUCING CLINICAL, ENDOSCOPIC, AND RADIOGRAPHIC RESPONSE IN REFRACTORY MODERATE-TO-SEVERE CROHN’S DISEASE: A MULTICENTRE COHORT STUDY

Autor: C Ma, R Fedorak, G G Kaplan, L A Dieleman, S Devlin, N Stern, K I Kroeker, C Seow, Y Leung, K L Novak, B P Halloran, V Huang, K Wong, S Ghosh, R Panaccione

BACKGROUND: Ustekinumab is a monoclonal antibody targeting the p40 subunit of interleukins 12 and 23. Gastroenterologists have begun to prescribe ustekinumab off-label for treatment of Crohn’s disease (CD) due to promising clinical trials but robus

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::391fc1c79560c2c7b2a9995c0e065367
https://europepmc.org/articles/PMC6507693/

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání